Clinical Trial

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 3, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
At present, there is no prospective study on the treatment of first-relapsed multiple myeloma with daratumumab plus pomalidomide and dexamethasone (Dara-Pd). A prospective, multicenter, open, non-interventional, observational clinical study to evaluate the efficacy and safety of Dara-Pd in patients with first relapse multiple myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-02-01; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2026-03-30
Trial Details
NCT Number NCT06252792
Lead Sponsor FengYan Jin
Collaborators: Affiliated Hospital of Hebei University, Second Hospital of Shanxi Medical University, Shandong Cancer Hospital and Institute, First Affiliated Hospital of Jinan University, Sun Yat-Sen University Cancer Center
Conditions Multiple Myeloma, First Relapse
Enrollment 50 participants
Start Date 2023-06-15
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-06-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-03